Reported 1 day ago
Iovance Biotherapeutics, a small-cap biotech known for its innovative cancer treatment Amtagvi, has struggled significantly, with shares currently trading below $2 amid a challenging market environment and complex product administration. While the potential for long-term growth exists, especially with expected revenue increases from Amtagvi, the company's financial risks and operational hurdles make it uncertain whether it can deliver millionaire-making returns. Investors are advised to approach with caution, considering that greater successes need to unfold for the stock to show substantial gains.
Source: YAHOO